Skip to content

Commit

Permalink
fixing all errors
Browse files Browse the repository at this point in the history
  • Loading branch information
@Melkiades
Melkiades committed Apr 3, 2024
1 parent 1d35c78 commit 41e8b27
Show file tree
Hide file tree
Showing 30 changed files with 1,714 additions and 2,438 deletions.
112 changes: 56 additions & 56 deletions tests/testthat/_snaps/listing_lbl01.md
View file

Large diffs are not rendered by default.

112 changes: 56 additions & 56 deletions tests/testthat/_snaps/listing_lbl01_rls.md
View file

Large diffs are not rendered by default.

112 changes: 56 additions & 56 deletions tests/testthat/_snaps/listing_lbl02a.md
View file

Large diffs are not rendered by default.

114 changes: 57 additions & 57 deletions tests/testthat/_snaps/listing_lbl02a_rls.md
View file

Large diffs are not rendered by default.

112 changes: 56 additions & 56 deletions tests/testthat/_snaps/listing_lbl02b.md
View file

Large diffs are not rendered by default.

62 changes: 31 additions & 31 deletions tests/testthat/_snaps/table_aet01.md
View file
Original file line number Diff line number Diff line change
Expand Up @@ -6,22 +6,22 @@
Placebo Xanomeline High Dose Xanomeline Low Dose
(N=86) (N=72) (N=96)
————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
Total number of patients with at least one AE 46 (53.5%) 64 (88.9%) 71 (74.0%)
Total number of AEs 96 233 228
Total number of patients with at least one AE 34 (39.5%) 61 (84.7%) 63 (65.6%)
Total number of AEs 71 189 177
Total number of deaths 2 (2.3%) 0 1 (1.0%)
Total number of patients withdrawn from study due to an AE 9 (10.5%) 5 (6.9%) 10 (10.4%)
Total number of patients with at least one
AE with fatal outcome 0 5 (6.9%) 3 (3.1%)
AE with fatal outcome 1 (1.2%) 2 (2.8%) 3 (3.1%)
Serious AE 0 0 0
Serious AE leading to withdrawal from treatment 0 0 0
Serious AE leading to dose modification/interruption 0 0 0
Related Serious AE 0 0 0
AE leading to withdrawal from treatment 4 (4.7%) 13 (18.1%) 13 (13.5%)
AE leading to dose modification/interruption 20 (23.3%) 44 (61.1%) 35 (36.5%)
AE leading to withdrawal from treatment 3 (3.5%) 12 (16.7%) 11 (11.5%)
AE leading to dose modification/interruption 15 (17.4%) 37 (51.4%) 34 (35.4%)
Related AE 0 0 0
Related AE leading to withdrawal from treatment 0 0 0
Related AE leading to dose modification/interruption 0 0 0
Severe AE (at greatest intensity) 0 3 (4.2%) 10 (10.4%)
Severe AE (at greatest intensity) 0 2 (2.8%) 8 (8.3%)

# Safety Summary Variant 2 (with Medical Concepts Section) works as expected

Expand All @@ -31,24 +31,24 @@
Placebo Xanomeline High Dose Xanomeline Low Dose
(N=86) (N=72) (N=96)
————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
Total number of patients with at least one AE 46 (53.5%) 64 (88.9%) 71 (74.0%)
Total number of AEs 96 233 228
Total number of patients with at least one AE 34 (39.5%) 61 (84.7%) 63 (65.6%)
Total number of AEs 71 189 177
Total number of deaths 2 (2.3%) 0 1 (1.0%)
Total number of patients withdrawn from study due to an AE 9 (10.5%) 5 (6.9%) 10 (10.4%)
Total number of patients with at least one
AE with fatal outcome 0 5 (6.9%) 3 (3.1%)
AE with fatal outcome 1 (1.2%) 2 (2.8%) 3 (3.1%)
Serious AE 0 0 0
Serious AE leading to withdrawal from treatment 0 0 0
Serious AE leading to dose modification/interruption 0 0 0
Related Serious AE 0 0 0
AE leading to withdrawal from treatment 4 (4.7%) 13 (18.1%) 13 (13.5%)
AE leading to dose modification/interruption 20 (23.3%) 44 (61.1%) 35 (36.5%)
AE leading to withdrawal from treatment 3 (3.5%) 12 (16.7%) 11 (11.5%)
AE leading to dose modification/interruption 15 (17.4%) 37 (51.4%) 34 (35.4%)
Related AE 0 0 0
Related AE leading to withdrawal from treatment 0 0 0
Related AE leading to dose modification/interruption 0 0 0
Grade 3-5 AE 9 (10.5%) 17 (23.6%) 20 (20.8%)
Grade 3-5 AE 8 (9.3%) 13 (18.1%) 16 (16.7%)
Total number of patients with at least one
SMQ01 (BROAD) 3 (3.5%) 6 (8.3%) 3 (3.1%)
SMQ01 (BROAD) 4 (4.7%) 10 (13.9%) 6 (6.2%)
SMQ02 (NARROW) 3 (3.5%) 5 (6.9%) 6 (6.2%)
CQ01 7 (8.1%) 6 (8.3%) 3 (3.1%)

Expand All @@ -60,18 +60,18 @@
Placebo Xanomeline High Dose Xanomeline Low Dose
(N=86) (N=72) (N=96)
————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
Total number of patients with at least one AE 46 (53.5%) 64 (88.9%) 71 (74.0%)
Total number of AEs 96 233 228
Total number of patients with at least one AE 34 (39.5%) 61 (84.7%) 63 (65.6%)
Total number of AEs 71 189 177
Total number of deaths 2 (2.3%) 0 1 (1.0%)
Total number of patients withdrawn from study due to an AE 9 (10.5%) 5 (6.9%) 10 (10.4%)
Total number of patients withdrawn informed consent 0 0 0
Total number of patients with at least one
AE with fatal outcome 0 5 (6.9%) 3 (3.1%)
AE with fatal outcome 1 (1.2%) 2 (2.8%) 3 (3.1%)
Serious AE 0 0 0
AE leading to withdrawal from treatment 4 (4.7%) 13 (18.1%) 13 (13.5%)
AE leading to withdrawal from treatment 3 (3.5%) 12 (16.7%) 11 (11.5%)
Related AE 0 0 0
Grade 3-5 AE 9 (10.5%) 17 (23.6%) 20 (20.8%)
Grade 4/5 AE 6 (7.0%) 9 (12.5%) 13 (13.5%)
Grade 3-5 AE 8 (9.3%) 13 (18.1%) 16 (16.7%)
Grade 4/5 AE 6 (7.0%) 7 (9.7%) 11 (11.5%)

# Safety Summary Variant 4 (with Rows Counting Events and Additional Sections) works as expected

Expand All @@ -81,27 +81,27 @@
Placebo Xanomeline High Dose Xanomeline Low Dose
(N=86) (N=72) (N=96)
————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
Total number of patients with at least one AE 46 (53.5%) 64 (88.9%) 71 (74.0%)
Total number of AEs 96 233 228
Total number of patients with at least one AE 34 (39.5%) 61 (84.7%) 63 (65.6%)
Total number of AEs 71 189 177
Total number of deaths 2 (2.3%) 0 1 (1.0%)
Total number of patients withdrawn from study due to an AE 9 (10.5%) 5 (6.9%) 10 (10.4%)
Total number of patients with at least one
AE with fatal outcome 0 5 (6.9%) 3 (3.1%)
AE with fatal outcome 1 (1.2%) 2 (2.8%) 3 (3.1%)
Serious AE 0 0 0
AE leading to withdrawal from treatment 4 (4.7%) 13 (18.1%) 13 (13.5%)
AE leading to dose modification/interruption 20 (23.3%) 44 (61.1%) 35 (36.5%)
AE leading to withdrawal from treatment 3 (3.5%) 12 (16.7%) 11 (11.5%)
AE leading to dose modification/interruption 15 (17.4%) 37 (51.4%) 34 (35.4%)
Related AE 0 0 0
Grade 3-5 AE 9 (10.5%) 17 (23.6%) 20 (20.8%)
Grade 3-5 AE 8 (9.3%) 13 (18.1%) 16 (16.7%)
Total number of unique preferred terms which are
Serious AE 0 0 0
AE leading to dose modification/interruption 12 14 13
AE leading to dose modification/interruption 9 10 10
Related AE 0 0 0
Grade 3-5 AE 7 9 12
Grade 4/5 AE 4 5 9
Grade 3-5 AE 6 6 8
Grade 4/5 AE 4 4 8
Total number of adverse events which are
Serious AE 0 0 0
AE leading to dose modification/interruption 27 64 58
AE leading to dose modification/interruption 20 49 46
Related AE 0 0 0
Grade 3-5 AE 11 19 24
Grade 4/5 AE 7 9 13
Grade 3-5 AE 10 15 19
Grade 4/5 AE 7 7 11

Loading

0 comments on commit 41e8b27

Please sign in to comment.